Clinical Trial: Induction of Migraine Attacks With Aura Using Pituitary Adenylate Cyclase Activating Polypeptide-38

U.S., Jan. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07342296) titled 'Induction of Migraine Attacks With Aura Using Pituitary Adenylate Cyclase Activating Polypeptide-38' on Jan. 08.

Brief Summary: Pituitary Adenylate Cyclase Activating Polypeptide-38 (PACAP-38) is a key neuropeptide in migraine pathophysiology and treatment. This study investigates whether PACAP-38 administration can trigger aura in individuals with a diagnosis of migraine with aura.

Study Start Date: Feb. 01

Study Type: INTERVENTIONAL

Condition: Migraine With Aura Migraine Aura

Intervention: DRUG: Pituitary Adenylate Cyclase Activating Polypeptide-38 (PACAP-38)

The participants will receive a continuous intravenous infusion o...